Iretig (Mirabegron)

Mirabegron activates β3‑adrenergic receptors located in the detrusor muscle of the bladder. Stimulation of these receptors causes smooth‑muscle relaxation, increasing bladder storage capacity and reducing involuntary contractions that lead to urgency and frequency.

The dosage of Iretig is determined by the prescribing healthcare professional based on the patient’s condition, renal function, and response to therapy. The prescriber will select the appropriate strength and dosing schedule in accordance with local labeling and clinical guidelines.

Safety of mirabegron in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Iretig product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike anticholinergics, which block muscarinic receptors and may cause dry mouth or constipation, mirabegron works by stimulating β3‑adrenergic receptors, offering an alternative mechanism with a different side‑effect profile. Some patients who cannot tolerate anticholinergics may benefit from mirabegron, though individual response varies.

Iretig tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date printed on the package.

Iretig is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise instructed.

The most serious adverse events reported with mirabegron include severe hypertension, urinary retention that may lead to bladder obstruction, and rare allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience these symptoms.

Iretig is contraindicated in patients with uncontrolled hypertension, severe urinary retention, or known hypersensitivity to mirabegron or any excipients. Caution is also advised in individuals with significant renal or hepatic impairment, and the drug should be avoided in those for whom the risk–benefit assessment is unfavorable.